NicOx S.A. (www.nicox.com) and Bausch + Lomb (www.bausch.com), a leading eye health company, have entered into a licensing agreement that grants Bausch + Lomb exclusive worldwide rights to develop and commercialize NCX 116 (previously PF-03187207), a nitric oxide-donating prostaglandin F2-analog.
NCX 116 has completed two Phase II studies in patients with glaucoma and ocular hypertension that demonstrated promising results.
Dr. Baldo Scassellati Sforzolini, Vice President Regulatory Affairs, Clinical & Medical Sciences at Bausch + Lomb, commented: “We look forward to this promising collaboration with NicOx, which further strengthens Bausch + Lomb’s product pipeline and potentially enables the company to provide patients with a worldwide prescription product for the treatment of glaucoma.”
Gavin Spencer, Vice President Business Development at NicOx, commented: “As one of the best-known and most respected healthcare companies in the world, dedicated specifically to eye health, Bausch + Lomb recognises the potential of NCX 116. We believe that their therapeutic focus offers a great opportunity to develop this molecule in glaucoma and we look forward to a strong collaboration.”
